164
Views
8
CrossRef citations to date
0
Altmetric
Reviews

The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidence

, , &
Pages 597-611 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Michela Meregaglia & John Cairns. (2015) Economic evaluations of follow-up strategies for cancer survivors: a systematic review and quality appraisal of the literature. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 913-929.
Read now
Brett Doble, Marcus Tan, Anthony Harris & Paula Lorgelly. (2015) Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist. Expert Review of Molecular Diagnostics 15:2, pages 235-254.
Read now

Articles from other publishers (6)

Vivek S Chaudhari, Kanchan C Hole & Amalia M Issa. (2022) Evaluating the quality of the economic evidence in colorectal cancer genomics studies. Personalized Medicine 19:4, pages 361-375.
Crossref
Annamaria Guglielmo, Nicoletta Staropoli, Monica Giancotti & Marianna Mauro. (2018) Personalized medicine in colorectal cancer diagnosis and treatment: a systematic review of health economic evaluations. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Rory D. Watts, Ian W. Li, Elizabeth A. Geelhoed, Frank M. Sanfilippo & Andrew St. John. (2017) Economic Evaluations of Pathology Tests, 2010-2015: A Scoping Review. Value in Health 20:8, pages 1210-1215.
Crossref
Virginie Nerich, Sopany Saing, Eva Maria Gamper, Georg Kemmler, Franck Daval, Xavier Pivot & Bernhard Holzner. (2016) Cost–utility analyses of drug therapies in breast cancer: a systematic review. Breast Cancer Research and Treatment 159:3, pages 407-424.
Crossref
Naazish S. BashirWendy J. Ungar. (2015) The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada. Genome 58:12, pages 527-540.
Crossref
Amalia M Issa. (2015) 10 years of personalizing medicine: how the incorporation of genomic information is changing practice and policy. Personalized Medicine 12:1, pages 1-3.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.